UNSPSC 51183619: Pramlintide

This classification denotes an anti-diabetic agent with the molecular formula C171H267N51O53S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) D3FM8FA78T, chemically known as l-tyrosinamide, l-lysyl-l-cysteinyl-l-asparaginyl-l-threonyl-l-alanyl-l-threonyl-l-cysteinyl-l-alanyl-l-threonyl-l-glutaminyl-l-arginyl-l-leucyl-l-alanyl-l-asparaginyl-l-phenylalanyl-l-leucyl-l-valyl-l-histidyl-l-seryl-l-seryl-l-asparaginyl-l-asparaginyl-l-phenylalanylglycyl-l-prolyl-l-isoleucyl-l-leucyl-l-prolyl-l-prolyl-l-threonyl-l-asparaginyl-l-valylglycyl-l-seryl-l-asparaginyl-l-threonyl-, cyclic (2-7)-disulfide but more generally known as pramlintide, which bears US NIH Compound Identifier 16132446.

UNSPSC 51183619 Pramlintide is a Commodity code covering pharmaceutical products—specifically pramlintide, a synthetic analog of amylin used in diabetes management—that state and local government health agencies procure through cooperative purchasing arrangements and multi-source competitive solicitations. Recent procurement activity shows that this code is being used as part of broader generic and branded pharmaceutical acquisition programs rather than for pramlintide in isolation; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) solicitation tags generic multi-source pharmaceuticals and OTC products under unified contracts where individual drugs including pramlintide may be included as line items within larger therapeutic categories. State and local health systems, Medicaid agencies, and correctional health programs source these products through authorized pharmaceutical wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) that service institutional and retail networks. Vendors responding to opportunities under this code must hold current Good Manufacturing Practice (cGMP) certification, comply with the Drug Supply Chain Security Act (DSCSA), maintain contractual relationships with at least two of three authorized wholesalers with chargeback systems in place, carry professional liability insurance of $2,000,000 and commercial general liability of $5,000,000, and submit detailed product data including National Drug Codes, SKUs, UPCs, strength, dosage form, and packaging configurations.

The Minnesota Department of Administration's Office of State Procurement, administering MMCAP on behalf of participating states including Oregon, posted an RFP (S1070000015802) on January 20, 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline. The award will establish multiple contracts effective July 1, 2026, spanning a two-year term with optional extensions; evaluation weights pricing competitiveness at 75 percent, fixed pricing at 10 percent, and administrative compliance (EDI capability, fee format adherence, 3 percent administrative fee agreement) at 15 percent combined. Vendors must provide products through authorized wholesalers with pricing options including flat price, net price formats (NF30, NF60, NF90), or WAC-minus structures, with products required to be available in the marketplace by May 15, 2026 and maintain minimum six-month shelf life from delivery. Performance penalties of $200 to $1,500 per violation apply for late reporting, missed onboarding, or improper class-of-trade denials. No specific dollar budget or set-aside designations were disclosed in the solicitation materials.